Discovery of a Novel Antifungal Agent in the Pathogen Box
Open Access
- 26 April 2017
- journal article
- research article
- Published by American Society for Microbiology in mSphere
- Vol. 2 (2) , e00120-17
Abstract
Cryptococcus neoformans and Candida albicans are two major human fungal pathogens and together account for over 1.4 million infections annually, with very high mortality rates. These fungi often infect immunocompromised individuals, such as HIV/AIDS patients. In an effort to identify novel drugs with antifungal activity, we have screened the Pathogen Box for compounds with anticryptococcal and anticandidal activities. This approach led to the discovery of a promising lead compound (MMV688271) with strong antifungal potency under nutrient-limited conditions.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (MA6248/1-1)
- Gouvernement du Canada | Canadian Institutes of Health Research (MOP-13234)
This publication has 37 references indexed in Scilit:
- Cryptococcus: from environmental saprophyte to global pathogenNature Reviews Microbiology, 2015
- Candida albicanspathogenicity mechanismsVirulence, 2013
- Hidden Killers: Human Fungal InfectionsScience Translational Medicine, 2012
- Tackling Human Fungal InfectionsScience, 2012
- Expanding fungal pathogenesis: Cryptococcus breaks out of the opportunistic boxNature Reviews Microbiology, 2011
- An insight into the antifungal pipeline: selected new molecules and beyondNature Reviews Drug Discovery, 2010
- Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDSAIDS, 2009
- The emergence of Cryptococcus gattii in British Columbia and the Pacific NorthwestCurrent Infectious Disease Reports, 2008
- Epidemiology of Invasive Candidiasis: a Persistent Public Health ProblemClinical Microbiology Reviews, 2007
- Nosocomial fungal infections: epidemiology, diagnosis, and treatmentMedical Mycology, 2007